Steffen Walter

Also affiliated with Immatics Biotechnologies (Germany)

MedicineBiochemistry, Genetics and Molecular BiologyImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “First-in-human dose escalation trial to evaluate the clinical safety and efficacy of an anti-MAGEA1 autologous TCR-transgenic T cell therapy in relapsed and refractory solid tumors”.

First-in-human dose escalation trial to evaluate the clinical safety and efficacy of an anti-MAGEA1 autologous TCR-transgenic T cell therapy in relapsed and refractory solid tumors

Journal for ImmunoTherapy of Cancer(2024)10.1136/jitc-2023-008668

N/A

0.742DataRank · unranked

29 citations

Tobias A.W. Holderried, Jason J. Luke, Van K. Morris, Winfried Alsdorf, Katrin Wetzko +27 more

Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer

Cancer Immunology Research(2023)10.1158/2326-6066.cir-22-0444

N/A

0.656DataRank · unranked

14 citations

Kerstin Guenther, Börje S. Andersson, Regina Mendrzyk, Amir Alpert, Claudia Wagner +36 more

Quantitative immunopeptidomics reveals a tumor stroma–specific target for T cell therapy

Science Translational Medicine(2022)10.1126/scitranslmed.abo6135

N/A

0DataRank · unranked

42 citations

Jens Fritsche, Sebastian Bunk, Andrea Mahr, Felix Unverdorben, Kevin Tosh +37 more